ASH 2019 – CLL

Preliminary results of the SEQUOIA trial suggested that zanubrutinib was active and generally well tolerated in treatment-naïve patients with del(17p) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL). Read More ›

The ongoing phase 1/2 HOVON 124/Ecwm-R2 trial showed the combination of ixazomib citrate, rituximab, and dexamethasone to be feasible, with promising efficacy and manageable toxicity in patients with relapsed or progressive Waldenström macroglobulinemia. Read More ›

Chimeric antigen receptor (CAR) T-cells represent a novel and exciting strategy for patients with blood cancers. This study evaluated lisocabtagene maraleucel, an investigational CAR T-cell product, for patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. Read More ›

In the minimal residual disease (MRD) cohort of the phase 2 CAPTIVATE study, first-line ibrutinib + venetoclax treatment resulted in high rates of undetectable MRD in both peripheral blood and bone marrow of patients with chronic lymphocytic leukemia (CLL). Read More ›

Results from TRANSCEND CLL 004 showed chimeric antigen receptor (CAR) T-cell treatment with lisocabtagene maraleucel in heavily pretreated patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) who had failed ibrutinib was manageable and produced durable undetectable minimal residual disease responses. Read More ›

In a study that compared VenR (venetoclax plus rituximab) with standard chemoimmunotherapy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), initial reports showed superior progression-free survival for VenR, as well as long-term benefits after patients stopped therapy. Read More ›

Results of the ECOG 1912 trial comparing chemoimmunotherapy with the oral BTK inhibitor ibrutinib plus rituximab in younger people with chronic lymphocytic leukemia (CLL). Read More ›

Results from the 3-year update of the phase 2 AIM trial confirmed the effectiveness of ibrutinib + venetoclax therapy for patients with mantle-cell lymphoma, and indicated that treatment interruption was feasible for patients in minimal residual disease–negative complete remissions. Read More ›

A large observational study showed increased first-line bendamustine-rituximab use among older patients with splenic or nodal marginal zone lymphoma was not associated with significant event-free survival or overall survival benefit versus single-agent rituximab, but led to increased toxicities and costs. Read More ›